As in the previous years ZoBio participated as a sponsor in Discovery on Target, the industry’s preeminent event on novel drug targets and technologies for drug discovery professionals. The conference highlighted advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.
Gregg Siegal presented the lecture: ‘Targeting RNA Readers’ on Wednesday September 16. In his presentation Gregg has shared insights of a developing inhibitors of YTHDF2, a protein that selectively recognized 6 methyl-adenosine in mRNA thereby regulates protein expression. Results from fragment screening and hit evolution campaign were presented.
Focused on discovery and optimization challenges of small molecule drug candidates, Drug Discovery Chemistry is a dynamic virtual event for medicinal and biophysical chemists working in pharma and biotech.
Gregg Siegal has presented the lecture: ‘Biophysics-Based Drug Discovery for Epitranscriptomics‘ during Fragment-Based Drug Discovery session. Afterwards, together with other speakers he participated in interesting and educational Q&A session.
St. Anton, Austria
Gregg Siegal presented the poster ‘The ZoBio Biophysics Toolbox for Fragment Screening and Hit Validation in Epitranscriptomics’ in this scenic environment that stimulated networking and scientific exchange between the participants. This was a small, but focused event that enabled intensive contact in the lecture hall and on the ski slopes of the Arlberg region.